X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EBX and Imperial are partnering to manage a Phase II, a investigator initiated trial, to evaluate how EBX-102 impacts on outcomes of bone marrow transplant patients with blood cancer.
Lead Product(s): EBX-102
Therapeutic Area: Oncology Product Name: EBX-102
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: EnteroBiotix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 10, 2022
Details:
Modus is currently developing sevuparin in sepsis/septic shock, and other conditions with systemic inflammation, with severe malaria being a further example. These conditions constitute major healthcare problems.
Lead Product(s): Sevuparin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Modus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 11, 2021
Details:
The initial study will help scientists understand how the immune system reacts to coronavirus (the virus that causes Covid-19), and identify factors that influence how the virus is transmitted.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2021
Details:
Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent. The findings come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).
Lead Product(s): Tocilizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
The collaboration will investigate the potential of combining Enesi's ImplaVax® technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial's self-amplifying RNA technology and novel Polyplex DNA/RNA stabilisation technologies.
Lead Product(s): RNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Enesi Pharma Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2020
Details:
In the study, the patients, who were in multiple hospitals across Italy and Spain, had a 71 per cent reduced risk of dying compared to patients who had not taken the drug (baricitinib).
Lead Product(s): Baricitinib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19.
Lead Product(s): TRV027
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TRV027
Highest Development Status: Phase IProduct Type: Peptide
Recipient: Trevena
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Imperial College London in the UK has advanced its Covid-19 vaccine candidate into the next phase of the COVAC1 clinical trial following the success in the initial dose escalation phase involving 15 volunteers.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Based on a new self-amplifying RNA (saRNA) technology, the vaccine was found to be safe and generated promising evidence of an effective immune response in pre-clinical safety tests and animal studies.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
